Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Jasper Therapeutics (NASDAQ:JSPR).
June 18, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Jasper Therapeutics, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100